Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique aims to prevent heart failure in High-Risk HCM patients

NCT ID NCT07372196

Disease control Sponsor: Meshalkin Research Institute of Pathology of Circulation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a new pacing method (left bundle branch pacing) with a standard pacemaker-defibrillator in 30 people who have hypertrophic cardiomyopathy and a specific heart block after myectomy surgery. The goal is to see if the new method better prevents heart failure worsening and dangerous heart rhythms. Participants will be randomly assigned to one of the two devices and followed for 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Men and women aged 18 years and older; * Patients with post-myectomy HCM who develop LBBB with a QRS complex greater than 130 ms and a high risk of SCD (HCM Risk-SCD ≥ 6%); * Signed informed consent to participate in the study; Exclusion criteria: * Absence of QRS complex morphology consistent with LBBB in LBBB with a positive QRS complex less than 130 ms; * Presence of baseline complete RBBB; * Heart transplantation or implantation of an LVAD is planned within the next 6 months; * Patients with intermediate or low risk of SCD; * History of AMI less than three months prior to study inclusion; * Acute renal and hepatic failure; * Acute infectious diseases; * Presence of mental illness; * Presence of other illnesses for which life expectancy is less than one year; * Patient refusal to participate in the study at any stage;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCM - hypertrophic cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Death, Sudden, Cardiac heart failure hypertrophic cardiomyopathy impulse control disorder sudden arrhythmia death syndrome sudden cardiac arrest

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCM - hypertrophic cardiomyopathy Heart failure (HF) ICD Left bundle branch pacing Sudden cardiac death

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Meshalkin Scientific Research Center of the Ministry of Health of Russia

    RECRUITING

    Novosibirsk, Novosibirsk Oblast, 630055, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.